Tel Aviv University (TAU)- Research Group

Prof. Dan Peer

Affiliation
Department of Cell Research and Immunology
The George S. Wise Faculty of Life Science
Center for Nanoscience and Nanotechnology
Tel Aviv University

Contact Information
Prof. Dan Peer
Building: Britannia
Room: 225
Office phone: 972-3-6405926
Lab phone: 972-3-6407925
Office fax: 972-3-6405926
Email: peer@post.tau.ac.il
Home page: www.tau.ac.il/~peer

Mailing adress
The George S. Wise faculty of life sciences
Department of Cell Research and Immunology
Tel Aviv University
Tel Aviv 69978, Israel

Research Interest

Selective targeting and reprogramming of cells using fully degradable nanomedicines
Our lab is studying how to manipulate cells’ functions in order to generate novel strategies to treat inflammatory diseases and cancers.

We are combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques for drug discovery and potentially for therapeutics. In addition, we are developing nanomedicines by designing highly selective targeting moieties and novel nanocarriers, with an ultimate goal to translate some of our findings into clinical settings.

We are particularly interested in

  • Developing novel strategies for targeted drug delivery.
  • Probing and manipulating the immune system with nanomaterials.
  • Studying the role of cell cycle regulators during inflammatory bowel diseases and blood cancers.
  • Investigating novel cancer multidrug resistance inhibitors.
  • Studying novel approaches to target adult stem cells (hematopoietic; bulge, cancer).
  • Harnessing RNAi as a tool for drug discovery and for therapeutic applications.
  • Developing tools to study immuno-nanotoxicity.
  • Investigating polysaccharides as building blocks for Nanotherapeutics

Selected Publications

Peer D. (2012) Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv Drug Deliv Rev. in press.

Barenholz Y and Peer D (2012). Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. Chemistry & Physics of Lipids 165, 363-364.

Moyano D., Goldsmith M., Solfiell D., Landesman-Milo D., Miranda O., Peer D.* and Rotello VM* (2012). Hydrophobicity Dictates Immune Response. Journal of American Chemical Society 134(9), 3965-3967. * denotes equal contribution.

Landsman–Milo D., and Peer D (2012). Modulating the immune response with liposomes. Journal of Controlled Release 161, 600-608.

Srinivasan C, Peer D, and Shimaoka M (2012). Integrin Targeted Stabilized Nanoparticles for an Efficient Delivery of siRNAs in vitro and in vivo. Methods in Molecular Biology. 820, 105-116.

Goldsmith M, Mizrahy S, Peer D (2011). Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine 6(10), 1771-1785.

Solmesky LJ, Shuman M, Goldsmith M, Weil M, Peer D (2011). Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach. Nanotechnology 22(49), 494016.

Mizrahy S, Peer D (2012). Polysaccharides as building blocks for nanotherapeutics. Chem Soc Rev. 41, 2623–2640

Moghimi SM, Peer D, Langer R (2011). Reshaping the Future of Nanopharmaceuticals: Ad ludicium. ACS Nano. 5(11), 8454-8458.

Ben-Arie N, Kedmi R. and Peer D (2012). Integrin-Targeted Nanoparticles for siRNA Delivery. Methods Mol Biol .757, 497-507.

Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, Dvash R, Landsman-Milo D, Bremer MG, Moghimi SM, Peer D. (2011). Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. Journal of Controlled Release. 156(2), 231-238.

Peer D, Lieberman J. (2011). Special delivery: targeted therapy with small RNAs. Gene therapy 18(12), 1127-1133.

Bachar G, Cohen K, Hod R, Feinmesser R, Mizrachi A, Shpitzer T, Katz O, Peer D. (2011). Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials 32(21), 4840-4848.

Drug E, Landesman-Milo D, Belgorodsky B, Ermakov N, Frenkel-Pinter M, Fadeev L, Peer D, Gozin M (2011). Enhanced Bioavailability of Polyaromatic Hydrocarbons in the Form of Mucin Complexes. Chemical research in toxicology. 24(3), 314-320.

Rivkin I, Cohen K, Koffler J, Melichov D., Peer D*, and Margalit R* (2010). Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 31, 7106-7114. * denotes equal contribution.

Kedmi R*, Ben-Arie N*, and Peer D (2010). The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867-6875. * denotes equal contribution.

Weinstein S., and Peer D (2010). RNAi Nanomedicines: challenges and opportunities within the immune system. Nanotechnology 21(23), 232001, 1-13.

Dearling JLJ, Voss S, Dunning P, Park EJ, Fahey F, Treves T Solapino S., Shimaoka M, Packard AB, and Peer D (2010). Detection of Intestinal Inflammation by microPET Imaging Using a 64Cu-Labeled Anti-b7 Integrin Antibody. Inflammatory bowel diseases 16(9), 1458-1466.

Kim S-S*, Peer D*, Kumar P*, Subramanya S, Wu H, Asthana D, Habiro K, Yang Y-G, N. Manjunath, Shimaoka M and Shankar P (2010). RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Molecular Therapy 18, 370-376. * denotes equal contribution.

Kedmi R, and Peer D (2009). RNAi nanoparticles in the service of personalized medicine. Nanomedicine. 4(8), 853-855.

Peer D (2009). Nanocarriers delivering RNAi to cancer cells: from challenge to cautious optimism. Therapy 6(3), 293-296.

Peer D, and Shimaoka M (2009). Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle 8, 853-859.

Peer D, Park EJ, Morishita Y, Carman CV, and Shimaoka M (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-Inflammation target. Science 319, 627-630.

Peer D, Karp JM, Hong S, Farokhzad O, Margalit R, and Langer R (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology 2, 751-760.

Peer D, Zhu P, Carman CV, Lieberman J, and Shimaoka M (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function- associated antigen-1. Proc. Natl. Acad. Sci. USA, 104, 4095-4100.

Peer D, and Margalit R (2006). Fluoxetine and reversal of multidrug resistance. Cancer Letters 237,180-187.

Peer D, Dekel Y, Melikhov D, and Margalit R (2004). Fluoxetine inhibits MDR extrusion pumps and enhances therapeutic responses to chemotherapy in syngeneic and human xenograft mouse tumor models. Cancer Research 64, 7562-7569.

Peer D, and Margalit R (2004). Tumor-targeted hyaluronan nano- liposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenografts mouse tumor models. Neoplasia 6, 343-353.

Full list of publication

Research Groups

Tel Aviv University (TAU)

Ben-Gurion University of the Negev (BGU)

The Hebrew University of Jerusalem (HUJI)

Bar-Ilan University (BIU)

The Chaim Sheba Medical Center (SMC)